_edited.png)
Psilomethoxin Lawsuits & Science: Novel Psychedelics Guide
A high-stakes legal and scientific clash is shaking the psychedelic landscape. The Church of Sacred Synthesis—formerly known as the Church of Psilomethoxin—is embroiled in court battles and chemical testing disputes over its controversial sacrament.
First reported by DoubleBlind Mag, the church claims its unique compound is created by feeding toad-derived 5-MeO-DMT to psilocybin mushroom substrate. The organization contends that the fungi biosynthesizes a novel, non-scheduled psychedelic called psilomethoxin.
However, years of competing laboratory analyses, federal trademark denials, and multi-million-dollar lawsuits have turned this sacrament into one of the most contentious drug policy debates in modern history.
Testing the Sacrament: Gas Chromatography vs. Orbitrap Mass Spectrometry
The scientific disagreement began in 2022 when chemist Hamilton Morris analyzed a sample using Gas Chromatography-Mass Spectrometry (GC-MS). His results showed no psilomethoxin, detecting only psilocybin and trace amounts of ketamine.
By 2023, three separate facilities confirmed those findings. Medicinal chemist Alexander Sherwood of the Usona Institute co-authored a pre-print paper titled "Fungi Fiction," which concluded the sacrament was simply traditional psilocybin mushrooms. Purdue University professor Dr. David Nichols also publicly described the church’s biological synthesis claims as nonscientific.
The Church of Sacred Synthesis responded by seeking new testing methods. Forensic toxicologist Jesse Hines of Competitive Labs analyzed samples alongside Elizabeth Gardner from the University of Alabama at Birmingham using Ultra-Performance Liquid Chromatography with High-Resolution Mass Spectrometry (UPLC-HRMS).
Hines used an Orbitrap Ion Trap Mass Spectrometer, which processes liquid samples without extreme heat. Hines and Gardner filed a sworn court affidavit asserting over 98 percent confidence that psilomethoxin is present in the tested material.
Reference Standards and the Scientific Method
Despite the findings from Hines, independent scientists emphasize that proving a new chemical compound requires rigorous verification. Scientific director Manesh Girn of The Center for MINDS noted that standard chemical protocols require comparison against a verified reference sample or structural confirmation using Nuclear Magnetic Resonance (NMR).
Synthesizing psilomethoxin has only been documented once, in 1965 by researchers at France's Pasteur Institute who derived it from vanilla orchids. Because that sample was not preserved or added to a reference library, no official standard exists today.
Without an established reference standard or third-party replication, critics argue that testing claims remain theoretical. Hines contends that earlier testing by Sherwood may have lacked optimal machine sensitivity, though Hines acknowledged the 98 percent certainty metric in the legal affidavit was assembled for legal defense framing.
Patent Battles, Trade Secret Lawsuits, and Court Rulings
The conflict shifted from academic journals to federal courts on April 6, 2026, when the church filed suit against Morris and Sherwood. Co-founder and attorney Ian Benouis alleged that public criticism by the scientists was secretly motivated by corporate interests looking to mine trade secrets for competing prodrug research.
Legal experts have expressed deep skepticism regarding these claims. Attorney Robert Rush of the Rights and Reason Project pointed out that the church openly marketed and sold the sacrament online, undermining typical trade secret protections.
Defendants filed a motion to dismiss on June 15, 2026, citing the legal principle that court remedy cannot be sought to protect potentially unlawful commercial operations. The US Patent and Trademark Office (USPTO) previously rejected the church’s trademark application, ruling that psilomethoxin is structurally similar to psilocybin, making it a Schedule I substance under the Controlled Substances Act.
On July 15, 2026, Presiding Judge Melissa Andrews dismissed all claims against Hamilton Morris due to lack of personal jurisdiction. Proceedings remain active against Sherwood, the Usona Institute, and Compass Pathways.
Church Sacraments, Nutraceuticals, and Commercialization
Beyond courtroom defense, the church’s founders have explored commercial scale. A private company named Psilosynth, created by Benouis, entered a Master Services Agreement with biotech firm CB Therapeutics in July 2023.
The proposed deal represents a projected $1.8 million contract over a 24-month production window. However, CB Therapeutics CEO Sher Ali Butt clarified that the company has not initiated experimental work, as commercial terms remain confidential.
The church has stated goals of marketing the compound as a "nutraceutical" to avoid federal oversight. Typically, religious groups seeking to distribute sacred substances must apply for exemptions under the Religious Freedom Restoration Act (RFRA) with the Drug Enforcement Administration (DEA).
Sacred Plant Alliance executive director Allison Hoots highlighted that the DEA evaluates religious sincerity and strict controls against non-religious diversion. Promoted valuations reaching hundreds of millions of dollars create severe legal friction with non-profit religious exemptions.
How This Compares to Other States
Navigating unapproved novel synthetics contrasts sharply with established state-level plant medicine and cannabis frameworks. Across the country, regulated markets rely on strict laboratory testing protocols and clear legal boundaries.
In states like Oregon and Colorado, legal psilocybin programs operate under direct state licensing and mandated testing for potency and contaminants. These systems prohibit unverified synthetic compounds from entering approved service centers.
Similarly, state cannabis programs require complete transparency from seed to sale. Whether consumers purchase flower, concentrates, or pre-rolls, licensed state labs must verify compound identities before products reach store shelves.
The psilomethoxin conflict highlights the risks of operating in legal grey zones without standardized lab reference samples or explicit legislative authorization.
What This Means for Washington DC, Maryland, and Virginia Residents
For plant medicine advocates across the DMV region, the psilomethoxin dispute offers crucial lessons on regulatory compliance and consumer safety. Local laws in Washington DC, Maryland, and Virginia remain distinct regarding plant-derived substances and cannabis.
In Washington DC, Initiative 71 allows the gifting of adult-use cannabis, while Initiative 81 designated natural entheogens like psilocybin mushrooms as the lowest law enforcement priority. However, DC weed laws do not legalize the commercial sale or mail-order distribution of synthetic tryptamines. Consumers exploring DC delivery services for compliant cannabis should remain cautious of unregulated online sacramental offerings.
Maryland operates a fully regulated adult-use cannabis framework governed by the Maryland Cannabis Administration. State regulations enforce strict lab testing for flower, edible dosing, and extract purity, while non-cannabis psychedelics remain strictly illegal outside approved clinical research.
Virginia residents currently operate under personal possession and home cultivation allowances, though adult-use retail sales remain pending legislative action. DMV residents should recognize that mail-order sacraments claiming federal legal exemptions often lack local legal protection or standardized quality control.
Timeline and Next Steps
Understanding the sequence of events helps contextualize where this legal battle is headed:
1965: Pasteur Institute chemists document the first synthesis of psilomethoxin from vanilla orchids.
2021-2022: The Church of Psilomethoxin begins online distribution of capsules; Hamilton Morris tests sample via GC-MS and finds no psilomethoxin.
2023: Sherwood and co-authors publish "Fungi Fiction"; church rebrands as Church of Sacred Synthesis and signs agreement with CB Therapeutics.
April 6, 2026: Church files federal trade secrets lawsuit against Morris and Sherwood.
June 15, 2026: Defendants file motion to dismiss based on illegal transaction precedents.
July 15, 2026: Judge Andrews dismisses claims against Hamilton Morris for lack of jurisdiction.
Late 2026: The church expects to file a motion for partial summary judgment within one to two months while remaining claims move forward.
Bud Lords Take: Commercialization vs. Community Compliance
Our take: The psilomethoxin saga illustrates why transparency and rigorous science are mandatory when serving the community. When organizations obscure product details or skip standard lab verifications, consumer trust vanishes.
At Bud Lords, we believe local DMV consumers deserve clear information, whether discussing medical programs, proper edible dosing, or clean cannabis extracts. Attempting to bypass federal safety rules by labeling novel psychedelics as "nutraceuticals" creates unnecessary regulatory risks for the entire reform movement.
True advocacy relies on honest compliance, rigorous peer-reviewed testing, and clear local policy alignment in Washington DC, Maryland, and Virginia.
What is psilomethoxin?
Psilomethoxin is a novel synthetic compound that the Church of Sacred Synthesis claims is biosynthesized by feeding 5-MeO-DMT to psilocybin mushroom substrate.
Is psilomethoxin legal under federal law?
No. The US Patent and Trademark Office noted that psilomethoxin is structurally similar to psilocybin, classifying it as a Schedule I substance under federal law.
Why do scientific tests disagree on psilomethoxin?
Multiple labs using standard GC-MS and UHPLC methods found only psilocybin. One toxicologist using UPLC-HRMS reported positive detection, but critics note that without a verified reference standard or NMR testing, the claim cannot be scientifically confirmed.
How does DC Initiative 81 relate to psilomethoxin?
DC Initiative 81 deprioritizes law enforcement against natural entheogenic plants and fungi. It does not legalize commercial mail-order sales or unverified synthetic chemical compounds.
Can psilomethoxin be sold legally as a nutraceutical?
No. The DEA and FDA strictly regulate controlled substances and dietary supplements. Selling novel scheduled analogs as dietary supplements violates federal safety and drug laws.
Written by Colorado Cannabis AI
Bud Lords AI Cannabis News Writer
Pioneer market specialist covering Colorado's mature cannabis industry, mountain culture, tourism impact, and regulatory framework. Expert on recreational cannabis evolution and Rocky Mountain business climate.
Expertise: colorado · mountain · recreational · tourism · denver · boulder
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments